Purpose: To evaluate the efficacy and safety of simultaneous resection in the treatment of nonmuscle invasive bladder cancer (NMIBC) with benign prostatic hyperplasia (BPH). Patients and Methods: Combined published data from comparative studies on simultaneous transurethral resection of bladder tumor/transurethral resection of the prostate (TURBT/TURP) vs TURBT alone in NMIBC were analyzed, considering possible confounding factors. Odds ratios (ORs) and 95% confidence intervals (CIs) were used as the primary effect size to estimate the outcome of overall tumor recurrence, recurrence in bladder neck/prostatic fossa. Results: In six eligible clinical trials, 483 patients were treated with simultaneous resection and 500 with TURBT alone. Within the follow-up period, tumor recurrence developed in 203 (42%) patients in the simultaneous resection group and 256 (51.2%) patients in the control group. The combined analysis indicated that the recurrence rate in the simultaneous resection group was statistically significantly lower than in the control group in the overall pooled data (combined OR = 0.67; 95% CI 0.52 to 0.88, P = 0.003). Tumor recurrence of bladder neck/prostatic fossa developed in 37(7.7%) patients in the simultaneous resection group and 42 (8.4%) patients in the control group. No statistically significant difference was found between the two groups (combined OR = 0.92; 95% CI 0.57 to 1.49, P = 0.74). Potential confounders, such as mean age, mean follow-up duration, multiplicity of tumor, and year of publication did not significantly influence the results. Conclusion: There was at least the evidence that simultaneous TURBT/TURP did not increase the overall recurrence rate and recurrence rate in bladder neck/prostatic fossa. Simultaneous TURBT/TURP might be preferable for patients with NMIBC and BPH.

Background: Long non-coding RNA (lncRNA) has been confirmed to exert a critical effect on the progression of tumors, including prostate cancer. Previous literature has demonstrated LINC01116 involves in activities of multiple cancers. However, the underlying role of LINC01116 in prostate cancer remains unclear.Methods: qRT-PCR measured the expression of LINC01116 in prostate cancer cells. EdU experiment was used to detect cell proliferation. Transwell assays detected cell migration and invasion. Immunofluorescence staining and western blot assays were utilized to measure EMT progress. The binding relationship between RNAs was confirmed by a series of mechanism assays. In addition, rescue experiments were conducted to verify the relationship among RNAs.Results: LINC01116 was found to be highly expressed in prostate cancer cells. Functional assays indicated that inhibition of LINC01116 could suppress cell proliferation, migration, invasion and EMT progress. Also, miR-744-5p was proven to bind with LINC01116. Moreover, UBE2L3 was verified as the target gene of miR-744-5p. In rescue assays, we discovered that inhibited miR-744-5p or overexpressed UBE2L3 could offset the suppressive influence of silencing LINC01116 on prostate cancer cells.Conclusion: Our study suggested that lncRNA LINC01116 acted as an oncogene in prostate cancer and accelerated prostate cancer cell growth through regulating miR-744-5p/UBE2L3 axis.

This study aimed to develop a simple nomogram based on the Mayo Adhesive Probability (MAP) score combined with the RENAL nephrometry score (RNS) to predict intraoperative complications before partial nephrectomy (PN) in Asian populations. This study retrospectively collected patients undergoing PN at three medical centers. Each component of the MAP score and the RNS (6 variables) was evaluated to assess its association with intraoperative complications by multivariable logistic regression with backward elimination. A total of 46 cases (7.2%) with intraoperative complications were identified among 637 patients. After backward elimination, three variables, including tumor diameter (4-7 cm vs. ≤4 cm: odds ratio [OR], 4.339; 95% confidence interval [CI], 1.943-9,692; ≥7 cm vs. ≤4 cm: OR, 8.434; 95% CI, 1.225-58.090), nearness to the collecting system (4-7 mm vs. ≥7 mm: OR, 2.988; 95% CI, 1.293-6.907; ≤4 mm vs. ≥7 mm: OR, 21.394; 95% CI, 6.122-74.756), and perirenal fat stranding type (type 1 vs. no stranding: OR, 3.119; 95% CI, 1.079-9.017; type 2 vs. no stranding: OR, 18.722; 95% CI, 6.757-51.868), were retained. The predictive power (measured by area under the curve [AUC]) of the nomogram was observed to be superior to the RNS or MAP score alone (RNS: 0.686, MAP score: 0.729, the nomogram: 0.837), but comparable to their combination (0.813). The simple nomogram contains fewer components than the combination of the RNS and MAP scores yet demonstrates equivalent predictive power for intraoperative complications.

Objective: This study aimed to develop a new rapid and simplified carbapenemase detection method (rsCDM) for detection and characterization of carbapenemase with 3-aminophenylboronic acid (APBA), ethylenediaminetetraacetic acid (EDTA), and cloxacillin (CLO) β-lactamase inhibitors.Methods: A panel of 182 carbapenem-resistant Enterobacterales (CRE) strains with blaKPC (88), blaNDM (60), blaIMP (10), blaVIM (3), blaOXA-181 (5), blaKPC, and blaNDM (7), porin changes in combination with an extended-spectrum β-lactamase (ESBL) (3) or AmpC hyper-production (6) and 43 carbapenem-susceptible Enterobacterales isolates were used to evaluate the performance of rsCDM and EDTA-carbapenem inactivation method (eCIM). Carbapenemase class was determined with specific inhibitors at 4, 6, and 18 h by rsCDM, and the difference between imipenem (IMI) and meropenem (MEM) disks was simultaneously compared.Results: The sensitivity of rsCDM using IMI was 97.1% at the three time points, with a specificity of 100%, independent of the culture duration. Similar to IPM, MEM disk also showed high sensitivity (97.1%) and specificity (100%) at 6 h. And the sensitivity of eCIM was 95.4% and the specificity was 100%. Based on a decision algorithm, the characterization number of IMI and MEM in KPC-producing isolates was 88 vs. 87, metallo-β-lactamases (MBLs) was 73 vs. 72, KPC and NDM carbapenemase was 7 vs. 7 at 4 h, respectively. After 6 h, the category number changed insignificantly except for isolates with combined AmpC overproduction and porin changes, showing an increase in IMI (6) and MEM (2), and there was no difference in the results between 6 and 18 h for the two tablets. OXA-181-producing strains can’t be distinguished by rsCDM. For eCIM, the characterization number in KPC-, OXA- 181-, and MBLs-producing strains was 88, 5, and 72, but it failed to detect multi-enzyme-producing isolates (KPC and NDM).Conclusion: rsCDM accurately discriminated carbapenemase within 4 h and could differentiate multi-enzyme (KPC and NDM) and AmpC in conjunction with porin changes strains. Hence, rsCDM represents a rapid, simple, easy readout, and accurate tool that can be used without any specialized equipment.

Background: Bladder cancer (BLCA) ranks first among genitourinary system tumors in terms of its incidence, and it is associated with poor prognosis due to its high recurrence and metastasis rates. In recent years, in-depth research on tumor microenvironment (TME) and immune infiltration has greatly improved the management of urinary system tumors, especially for advanced BLCA. Therefore, this study aimed to construct a risk scoring model with related immune genes as the independent prognostic factors, so as to estimate BLCA survival according to immune gene expression characteristics. Methods: Here, we downloaded clinical and mRNA data of BLCA in TCGA database and utilized them as the model test set. Clinical samples with incomplete tumor staging or grading information were excluded from this study. Differentially expressed genes (DEGs) between BLCA and normal tissues were identified for GO and KEGG functional enrichment. Further, the prognostic DEGs were obtained by screening the identified DEGs. Thereafter, univariate, multivariate and Lasso regression analyses were performed on immune genes from the as-identified prognostic DEGs. As a result, four independent related immune genes (OAS1, APOBEC3H, LBP1, ANHAK) were obtained, which were then incorporated in the construction of an immune risk scoring model. Finally, TCGA-clear cell renal cell carcinoma (CCRCC) was used as a validation set to validate the risk model.Results: Upon multivariate analyses of both test and validation sets, the four independent genes used to construct the risk scoring model were the independent prognostic factors. As revealed by Kaplan-Meier (KM) curve of BLCA, patient survival time showed significant negative relation to risk score, as verified in validation set. Moreover, the receiver operating characteristic (ROC) curve suggested that, the area under the curve (AUC) was greatly improved when the risk score was used in combination with clinical characteristics, revealing that the risk score might have a better diagnostic value in clinic. Conclusion: This study builds an immune risk assessment model based on the relationship between immunity and BLCA. Finally, four immune-associated prognostic genes were obtained, and the applicability of the model constructed using these four genes to predict urinary system tumors was verified.